Hamid Zarqane

Dr. Hamid Zarqane


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
RRREMI ROLLAND
REMI ROLLAND
ALAntoine Loubet
Antoine Loubet
SBSébastien Bommart
Sébastien Bommart
VMValérie Monnin-Bares
Valérie Monnin-Bares
HZHamid Zarqane
Hamid Zarqane
HKHélène Kovacsik
Hélène Kovacsik
Transarterial embolization (TAE) of renal angiomyolipoma (AML) is effective in treating and preventing hemorrhage. We report our experience using EVOH with a single-center retrospective study of all AML embolized with EVOH between June 2013 and March 2022 at the Montpellier University Hospital. A total of 29 embolizations were carried out in 24 consecutive patients (mean age: 53.86 years; 21 women and 3 men) with 25 AMLs for severe bleeding, symptomatic AML, tumor size > 4 cm, or presence of aneurysm(s) > 5 mm. Data collected included imaging and clinical outcomes, tuberous sclerosis complex status, change in AML volume, rebleeding, renal function, volume and concentration of EVOH used, and complications. Out of 29 embolizations performed for 25 AMLs, four were performed in an emergency. Technical success was achieved for 24/25 AMLs. Mean AML volume reduction was 53.59% after a mean follow-up time of 446 days using MRI or CT scan. Aneurysms on angiogram and the symptomatological nature of AML, as well as secondary TAE and multiple arterial pedicles, were statistically associated (p < 0.05). Two patients (8%) underwent nephrectomy after TAE. Four patients had a second embolization. Minor and major complication rates were 12% and 8%, respectively. Neither rebleeding nor renal function impairment was noticed. TAE of AML using EVOH is, thus, highly effective and safe.

14 June 2022 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
VMValerie Monnin-Bares
Valerie Monnin-Bares
MRMathieu Rodiere
Mathieu Rodiere
MFMathieu Finas
Mathieu Finas
FDFrederic Douane
Frederic Douane
ALAlexandre Lablee
Alexandre Lablee
SBSebastien Bommart
Sebastien Bommart

27 October 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
FBFrançois Bughin
François Bughin
HKHélène Kovacsik
Hélène Kovacsik
IJIsabelle Jaussent
Isabelle Jaussent
KSKamila Solecki
Kamila Solecki
SASylvain Aguilhon
Sylvain Aguilhon
Yves DauvilliersYves Dauvilliers
Yves Dauvilliers
Background: Obstructive sleep apnea syndrome (OSA) is common in patients with acute myocardial infarction (AMI). Whether OSA impacts on the ventricular remodeling post-AMI remains unclear. We compared cardiac ventricular remodeling in patients assessed by cardiac magnetic resonance (CMR) imaging at baseline and six months after AMI based on the presence and severity of OSA. Methods: This prospective study included 47 patients with moderate to severe AMI. They all underwent CMR at inclusion and at six months after an AMI, and a polysomnography was performed three weeks after AMI. Left and right ventricular remodeling parameters were compared between patients based on the AHI, AHI in REM and NREM sleep, oxygen desaturation index, and daytime sleepiness. Results: Of the 47 patients, 49% had moderate or severe OSA with an AHI ≥ 15/h. No differences were observed between these patients and those with an AHI < 15/h for left ventricular end-diastolic and end-systolic volumes at six months. No association was found for left and right ventricular remodeling parameters at six months or for the difference between baseline and six months with polysomnographic parameters of OSA severity, nor with daytime sleepiness. Conclusions: Although with a limited sample size, our proof-of-concept study does not report an association between OSA and ventricular remodeling in patients with AMI. These results highlight the complexity of the relationships between OSA and post-AMI morbi-mortality.